

Curriculum Vitae

Maria Gisella Cavallo

Education

University graduation

1986 Sapienza University of Rome Degree in Medicine and Surgery cum laude

Post-graduate studies

PhD 1991 Sapienza University of Rome PhD in Endocrinology and Metabolism

Specialty 1989 Sapienza University of Rome Degree in Endocrinology cum laude

Specialty 1998 Sapienza University of Rome Degree in Oncology cum laude

Licensure 1986 Ordine dei Medici di Roma Registration n.38541

Appointments

Academic Appointments

2000 - present Sapienza University of Rome Assistant Professor of Internal Medicine (Ricercatore a tempo indeterminato)

1997 - 2000 University Campus Biomedico Facoltà di Medicina e Chirurgia Adjunct professor of "Patologia Medica Integrata"

1993 - 1995 Sapienza University of Rome Istituto II Clinica Medica Postdoctoral Research Fellow and clinical Assistant

Clinical Appointments

2000 - present

Azienda Policlinico Umberto I Dirigente Medico UOC Medicina Interna

DAI Medicina interna e specialità mediche

Other Appointments

2018 - Diabetes Metabolism Research/Reviews: Member of Editorial Board

2014 -2019 Società Italiana di Diabetologia: Member of Editorial Committee

2013 -2015 Sapienza University Rome, Italy: Member of the research Committee

1996 Department of Autoimmunity, Bristol Mayers Squibb Pharmaceutical Research Institute, Seattle: Visiting scientist

1991-1992 Department of Diabetes and Immunogenetics, St. Bartholomew's Hospital, London,UK: Visiting scientist

1988 -1991 Division of Immunobiology, National Institute for Biological Standards and Control, London, UK: Research Fellow

1987 -1987 Department of Immunology, United Medical and Dental Schools of Guy's and St. Thomas's Hospitals, University of London: Visiting Research Fellow

National Scientific Qualification for academic positions

2013 - Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR) - National Scientific Qualification for Associate Professor for the SC 06/D2, SSD MED/13, Endocrinology

2017 - Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR) - National Scientific Qualification for Associate Professor for the SC 06/B1, SSD MED/09, Endocrinology

2018 - Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR) National Scientific Qualification for full Professor for the SC 06/D2, SSD MED/13, Endocrinology

2018 - Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR) National Scientific Qualification for full Professor for the SC 06/B1, SSD MED/09, Internal Medicine

Teaching experience

1997-2001 University Campus Biomedico, Rome, Italy

Docente nel corso di Patologia Medica Integrata, facoltà di Medicina e Chirurgia

2000-2003 Sapienza University Rome, Italy

Docente nel corso di Perfezionamento in "Prevenzione e Terapia dell'Obesità

2001- Sapienza University Rome, Italy

Docente del corso integrato "Metodologia VI" per il corso di Laurea Specialistica in Medicina e chirurgia, III anno

2001-2008 Sapienza University Rome, Italy

Docente Scuola di Specializzazione in Gastroenterologia III

2005- Sapienza University Rome, Italy

Membro del Collegio dei Docenti Corso di Specializzazione in Medicina Termale

2012- Sapienza University Rome, Italy

Membro del Collegio dei Docenti Corso di Specializzazione in Medicina Interna

2016- Sapienza University Rome, Italy

Docente del corso integrato "Medicina Interna III", VI anno II semestre, CLMC

2017- Sapienza University Rome, Italy

Membro del Collegio dei Docenti del Dottorato di Ricerca in Scienze Endocrinologiche

2018- Sapienza University Rome, Italy

Membro del Collegio dei Docenti Corso di Specializzazione in Endocrinologia e Malattie del Metabolismo

Society memberships, Awards and Honors

1986- Italian Society of Diabetology (SID) Member

1986-1990 European Association for the Study of Diabetes (EASD) Member

1986-1992 Italian Society of Endocrinology (SIE) Member

1989-1991 Sapienza University "Istituto Pasteur-Fondazione Cenci Bolognetti"
Research Fellowship

1990 Italian Society of Diabetology (SID) Meeting award

1990 European Association for the Study of Diabetes (EASD) EASD meeting Copenhagen 1990
Travel grant

1990 Parma Diabete Università di Parma Jounng Investigator award

1991 Consiglio Nazionale delle Ricerche (CNR) Borsa di Studio per l'estero

1992 Italian Society of Diabetology (SID) Borsa di studio per lo svolgimento di attività di
ricerca presso centri esteri

1994-2000 Immunology of Diabetes Society (IDS) Member

1993-1995 Juvenile Diabetes Research Foundation International (JDRF) Award Fellowship

2005-2017 Socio della Società Italiana di Medicina Interna (SIMI) Member

2005-2017 Collegio dei docenti Universitari in Medicina Interna 09” (COLMED 09) Member

Research Activities

NAFLD; Adipose tissue Inflammation

Pathophysiological aspects of body fat regulation in subjects with type 2 diabetes and metabolic syndrome. Mechanisms linking NAFLD to systemic inflammation and adipose tissue dysfunction

Vitamin D deficiency; VD/VDR axis

Study of the association between vitamin D status and metabolic diseases. Variation in genes regulating vitamin D metabolism. Effects of vitamin D supplementation on metabolic variables.

Type 2 diabetes; Glucose regulation; Metabolic syndrome Study of the phenotypical heterogeneity of patients with type 2 diabetes. Genetics of type 2 diabetes and impaired glucose regulation. Identification of new biomarkers of diabetes progression and development of cardiovascular complications.

Type 1 diabetes; Immunity; Immunotherapy Study of the etiopathogenesis of type 1 diabetes including alterations in the immune response, cytokine secretion, environmental factors and the identification of new strategies to prevent end stage loss of islet function in patients with recent onset type 1 diabetes.

Funding

2005

Analisi di geni candidati per il difetto di secrezione insulinica e di insulino resistenza negli stati di alterata regolazione del glucosio e nel diabete

Principal Investigator, Sapienza University, Ricerche di FACOLTÀ, €1520

2005

Studio della variabilità di fattori endocrinometabolici di crescita tessutale in campioni omogenei di atleti in condizioni basali e di allenamento.

Responsabile di Unità Operativa, Italian Ministry of Health 2005 “Programma di ricerca sui farmaci, sulle sostanze e sulle pratiche mediche utilizzabili a fini di doping nelle attività sportive” €30000

2006

Analisi di geni candidati per il difetto di secrezione insulinica e di insulino resistenza negli stati di alterata regolazione del glucosio e nel diabete

Principal Investigator, Sapienza University, Ricerche di FACOLTÀ, €1540

2007

Ricerca di determinanti genetici di diabete tipo 2 ad insorgenza precoce [early-onset type 2 diabetes (EOD)], tramite analisi di geni candidati

Principal Investigator, Sapienza University, Ricerche di FACOLTÀ, €1400

2008

Ricerca di determinanti genetici di diabete tipo 2 ad insorgenza precoce [early-onset type 2 diabetes (EOD)], tramite analisi di geni candidati (II)

Principal Investigator, Sapienza University, Ricerche di FACOLTÀ, €1500

2008

La regolazione dell'accumulo e della distribuzione del grasso corporeo: aspetti patogenetici, nutrizionali e terapeutici in relazione al rischio cardiometabolico

Responsabile di Unità Operativa, Italian Ministry of Education, Universities and Research, Research Projects of National Interest (PRIN) €24000

2009

Ruolo della ipovitaminosi D nella patogenesi e nell'evoluzione della sindrome metabolica, del diabete mellito di tipo 2 e della steatosi epatica non alcol correlata (NAFLD)

Principal Investigator, Sapienza University, Ricerche di FACOLTÀ, €5000

2011

Efficacia della supplementazione orale con vit. D3 nel ridurre la steato-infiammazione

epatica e nel modificare il profilo di rischio cardio-metabolico in adulti diabetici affetti da steatosi/steatoepatite non alcoolcorrelata (NAFLD/NASH)
Principal Investigator, Sapienza University, Ricerche UNIVERSITARIE €5000

2015

The "Sapienza University Mortality and Morbidity Event Rate (SUMMER) study in diabetes"
Finanziamento Fondazione Banca D'Italia €25000

2016

Clinical, histological, immunological and genetic determinants of adipose tissue associated immune responses and liver inflammation in obese patients candidate to bariatric surgery
Principal Investigator, Sapienza University, Ricerche UNIVERSITARIE €33600

2016

A randomized, double blind placebo controlled clinical trial to assess the efficacy and safety of sitagliptin on bone measures in women affected by type 2 diabetes. A gender-oriented approach to address a gender-specific frailty. The SLOWDOWN (SitagLiptin in Diabetes for Osteoporosis in Women) study"
Responsabile Scientifico AIFA Finanziamento per la Ricerca Indipendente 2016 €495000

2017

Interazione tra Dipeptidil Peptidasi-4 e Vitamina D nell'asse osso-tessuto adiposo in soggetti con diabete di tipo 2
Principal Investigator Finanziamento Fondazione Banca D'Italia €64000

2018

DPP-4 activity in inflammation and bonemetabolism: role of the DPP-4 in Vitamin D balance and bone health in relation to glucose metabolism and other metabolic complications of obesity
Principal Investigator, Sapienza University, Ricerche UNIVERSITARIE €10000

2019

From chronic inflammation to metabolic disorders: study of the gut-liver axis in the pathophysiology of adipose tissue dysfunction
Principal Investigator, Sapienza University, Ricerche UNIVERSITARIE €34527

Partecipazione to International Clinical Trials

2007-2011

Principal Investigator - International, Randomised Clinical Trial - Andromeda 901: double-blind Diapep 277 vs placebo in type 1 diabetes at diagnosis

2008-2011

Principal Investigator - International, Multicenter, Randomised Clinical Trial DEFEND-1: a Phase 3 Trial with Otelixizumab (a humanized anti-CD3 MAb) in type 1 diabetes

2010-2012

Principal Investigator - International, Multicenter, Randomised Clinical Trial DEFEND-2: a Phase 3 Trial with Otelixizumab (a humanized anti-CD3 MAb) in type 1 diabetes

2011-2014

Principal Investigator - International, Multicenter, Randomised Clinical Trial Andromeda 1001:

A Phase 3, Multinational, Randomized, Double-Blind, PlaceboControlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety Of Diapep277®In Newly Diagnosed Type 1 Diabetes Subjects

2016-2018

Principal Investigator - International, Multicenter, Prospective Study REFLECT: Studio prospettico, non interventistico, multicentrico per la valutazione della sicurezza e dell'efficacia di insulina degludec in una popolazione di pazienti con diabete mellito tipo 1 e 2 nella reale pratica clinica.

2017-2019

Principal Investigator - International, Multicenter Randomised Clinical Trial PRONTO-T1D (I8B-MC-ITRM) - A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes”

2018-2019

Principal Investigator - International, Multicenter, Clinical Trial SAGE: Multinational, crosssectional, observational study to describe glycemic control and quality of life for type 1 diabetic adult patients.

2018

Principal Investigator - International, Multicenter, Clinical Trial INSAX - In-market utilisation of liraglutide used for weight management in Europe: a retrospective medical record review study

2019

Principal Investigator - International, Multicenter, Clinical Trial EU-CAPTURE - A noninterventional cross-sectional study to capture the prevalence of cardiovascular disease in patients with type 2 diabetes in selected countries in Europe

2019

Principal Investigator - International, Multicenter, Randomised Clinical Trial FLOW -Effetti di semaglutide rispetto al placebo sulla progressione dell'insufficienza Renale in soggetti con diabete di tipo 2 e malattia renale cronica

Publications in peer reviewed journals

1. BARCHETTA I, CECCARELLI V, CIMINI FA, BARONE E, SENTINELLI F, COLUZZI M, CHIAPPETTA C, BERTOCCINI L, TRAMUTOLA A, LABBADIA G, DI CRISTOFANO C, SILECCHIA G, LEONETTI F, **CAVALLO MG**. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. *J Endocrinol Invest*. 2020;10.1007/s40618-020-01392-5. doi:10.1007/s40618-020-01392-5
2. BARCHETTA I, CHIAPPETTA C, CECCARELLI V, CIMINI FA, BERTOCCINI L, GAGGINI M, CRISTOFANO CD, SILECCHIA G, LENZI A, LEONETTI F, BARONI MG, GASTALDELLI A, **CAVALLO MG**. Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. *Int J Mol Sci*. 2020 Sep 29;21(19):E7197. doi: 10.3390/ijms21197197. PMID: 33003532.
3. BARCHETTA I, CECCARELLI V, CIMINI FA, BARONE E, SENTINELLI F, COLUZZI M, CHIAPPETTA C, BERTOCCINI L, TRAMUTOLA A, LABBADIA G, DI CRISTOFANO C, SILECCHIA G, LEONETTI F, **CAVALLO MG**. Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity [published online ahead of print, 2020 Jun 8]. *Liver Int*. 2020;10.1111/liv.14554. doi:10.1111/liv.14554
4. CIMINI FA, BARCHETTA I, CECCARELLI G, LEONETTI F, SILECCHIA G, CHIAPPETTA C, DI CRISTOFANO C, CAPOCCIA D, BERTOCCINI L, CECCARELLI V, CARLETTI R, FRAIOLI A, BARONI MG, MORINI S, **CAVALLO MG**. Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease [published online ahead of print, 2020 May 29]. *Diabetes Metab Res Rev*. 2020;e3358. doi:10.1002/dmrr.3358
5. BARCHETTA I, **CAVALLO MG**, BARONI MG. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications. *Diabetes Res Clin Pract*. 2020;163:108165. doi:10.1016/j.diabres.2020.108165
6. CIMINI FA, BARCHETTA I, CAROTTI S, MORINI S, **CAVALLO MG**. Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease. *World J Gastrointest Pathophysiol*. 2019 Sep 10;10(2):11-16. doi: 10.4291/wjgp.v10.i2.11.
7. BARCHETTA I, CECCARELLI G, BARONE E, CIMINI FA, CECCARELLI V, BERTOCCINI L, SENTINELLI F, TRAMUTOLA A, DEL BEN M, ANGELICO F, BARONI MG, LENZI A, **CAVALLO MG**. Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. *Nutr Metab Cardiovasc Dis*. 2019 Oct;29(10):1087-1094 doi:10.1016/j.numecd.2019.07.010.
8. BARCHETTA I, CIMINI FA, CECCARELLI G, BARONI MG, **CAVALLO MG**. Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation. *J Endocrinol Invest*. 2019 May 9. doi: 10.1007/s40618-019- 01052-3
9. BAILETTI, D, BERTOCCINI, L, MANCINA, R M, BARCHETTA, I, CAPOCCIA, D, COSSU, E, PUJIA, A, LENZI, A, LEONETTI, F, **CAVALLO, MG**, ROMEO, S, BARONI, MG (2019). ANGPTL4 gene E40K variation protects against obesity-associated dyslipidemia in

participants with obesity. *OBESITY SCIENCE & PRACTICE*, vol. 5, p. 83-90, ISSN: 2055-2238, doi: 10.1002/osp4.311

10. BERTOCCINI, L., SENTINELLI, F., INCANI, M., BAILETTI, D., CIMINI, F.A., BARCHETTA, I., LENZI, A., **CAVALLO M.G.**, COSSU E., BARONI M.G. (2019). Circulating miRNA-375 levels are increased in autoantibodies- positive first-degree relatives of type 1 diabetes patients. *ACTA DIABETOLOGICA*, vol. 56, p. 707-710, ISSN: 0940-5429, doi: 10.1007/s00592-019-01297-7
11. BARCHETTA I, ENHÖRNING S, CIMINI F A, CAPOCCIA D, CHIAPPETTA C, DI CRISTOFANO C, SILECCHIA, GIANFRANCO, LEONETTI F, MELANDER O, **CAVALLO MG** (2019). Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity. *BMC MEDICINE*, vol. 17, ISSN: 1741-7015, doi: 10.1186/s12916-019-1319-4
12. BARCHETTA I, CECCARELLI V, CIMINI FA, BERTOCCINI L, FRAIOLI A, ALESSANDRI C, LENZI A, BARONI MG, **CAVALLO MG**. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus. *J Endocrinol Invest*. 2019 May;42(5):513-520. doi:10.1007/s40618-018- 0941-x.
13. CIMINI FA, D'ELISEO D, BARCHETTA I, BERTOCCINI L, VELOTTI F, **CAVALLO MG** (2019). Increased circulating granzyme B in type 2 diabetes patients with low-grade systemic inflammation. *CYTOKINE*, vol. 115, p. 104- 108, ISSN: 1043-4666, doi: 10.1016/j.cyto.2018.11.019
14. CIMINI FA, ARENA A, BARCHETTA I, TRAMUTOLA A, CECCARELLI V, LANZILLOTTA C, FONTANA M, BERTOCCINI L, LEONETTI F, CAPOCCIA D, SILECCHIA G, DI CRISTOFANO C, CHIAPPETTA C, DI DOMENICO F, BARONI M G, PERLUIGI M, **CAVALLO MG**, BARONE E (2019). Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity. *BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE*, ISSN: 0925-4439, doi: 10.1016/j.bbadis.2019.02.021
15. BARCHETTA I, **CAVALLO MG**. (2019). Technological Support to Intensive Insulin Therapy by a Novel Smartphone Application in Young Adults With Type 1 Diabetes: One Center's Experience. *JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY*, ISSN: 1932-2968, doi: 10.1177/1932296818803937
16. BEVERIDGE LA, KHAN F, STRUTHERS AD, ARMITAGE J, BARCHETTA I, BRESSENDORFF I, **CAVALLO MG** et al. Effect of vitamin D supplementation on markers of vascular function - a systematic review and individual participant meta-analysis. *JAHA* 2018 7 March; doi:10.1161/JAHA.117.008273.
17. BARCHETTA, I; CIMINI, F A; DE GIOANNIS, R; CICCARELLI, G; BERTOCCINI, L; LENZI, A; BARONI, M G; **CAVALLO, MG** Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease 2018 - *Diabetes/Metabolism Research and Reviews*, Wiley, 2018, Vol. 5, ISSN: 1520-7552, doi: 10.1002/dmrr.2998.
18. BARCHETTA I, CIMINI FA, CAPOCCIA D, BERTOCCINI L, CECCARELLI V, CHIAPPETTA C, LEONETTI F, DI CRISTOFANO C, SILECCHIA G, ORHO-MELANDER M, MELANDER O, **CAVALLO MG**. Neurotensin Is a Lipid- Induced Gastrointestinal Peptide Associated with Visceral Adipose Tissue Inflammation in Obesity. *Nutrients*. 2018 Apr 23;10(4).
19. BARCHETTA I, CIMINI FA, LEONETTI F, CAPOCCIA D, DI CRISTOFANO C, SILECCHIA G, ORHO-MELANDER M, MELANDER O, **CAVALLO MG**. Increased plasma proneurotensin

levels identify NAFLD in adults with and without type 2 diabetes. *J Clin Endocrinol Metab.* 2018 Mar 23. doi: 10.1210/jc.2017-02751.

20. BARCHETTA I, CICCARELLI G, CIMINI FA, CECCARELLI V, ORHO-MELANDER M, MELANDER O, **CAVALLO MG**. Association between systemic leptin and neurotensin concentration in adult individuals with and without type 2 diabetes mellitus. *J Endocrinol Invest.* 2018 Feb 7. doi: 10.1007/s40618-018-0845-9
21. COSSU E, INCANI M, PANI MG, GATTU G, SERAFINI C, STRAZZERA A, BERTOCCINI L, CIMINI FA, BARCHETTA I, **CAVALLO MG**, BARONI MG. Presence of diabetes-specific autoimmunity in women with gestational diabetes mellitus (GDM) predicts impaired glucose regulation at follow-up. *J Endocrinol Invest.* 2018 Jan 16. doi:10.1007/s40618-018-0830-3.
22. BARCHETTA I, CIMINI FA, CAPOCCIA D, DE GIOANNIS R, PORZIA A, MAINIERO F, DI MARTINO M, BERTOCCINI L, DE BERNARDINIS M, LEONETTI F, BARONI MG, LENZI A, **CAVALLO MG**; WISP1 Is a Marker of Systemic and Adipose Tissue Inflammation in Dysmetabolic Subjects With or Without Type 2 Diabetes, *J Endocr Soc.* 2017 Apr 18;1(6):660-670. doi: 10.1210/js.2017-00108.
23. BERTOCCINI L, SENTINELLI F, INCANI M, BAILETTI D, CIMINI FA, BARCHETTA I, **CAVALLO MG**, COSSU E, LENZI A, LOCHE S, BARONI MG. The Arg282Ser missense mutation in APOA5 gene determines a reduction of triglyceride and LDL-cholesterol in children, together with low serum levels of apolipoprotein A-V. *Lipids Health Dis.* 2017 Sep 19;16(1):179. doi: 10.1186/s12944-017-0569-4
24. BARCHETTA I, CIMINI FA, **CAVALLO MG**. Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future. *Nutrients.* 2017 Sep 14;9(9). doi: 10.3390/nu9091015. Review.
25. CIMINI FA, BARCHETTA I, PORZIA A, MAINIERO F, COSTANTINO C, BERTOCCINI L, CECCARELLI V, MORINI S, BARONI MG, LENZI A, **CAVALLO MG**. Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile. *Acta Diabetol.* 2017 Aug 23. doi: 10.1007/s00592-017-1039-1. PubMed PMID: 28836077.
26. CIMINI FA, BARCHETTA I, CAROTTI S, BERTOCCINI L, BARONI MG, VESPASIANI-GENTILUCCI U, **CAVALLO MG**, MORINI S. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. *World J Gastroenterol.* 2017 May 21;23(19):3407-3417.
27. BARCHETTA I, DEL BEN M, ANGELICO F, DI MARTINO M, FRAIOLI A, LA TORRE G, SAULLE R, PERRI L, MORINI S, TIBERTI C, BERTOCCINI L, CIMINI FA, PANIMOLLE F, CATALANO C, BARONI MG, **CAVALLO MG**. Comment on Elangovan H et al. Vitamin D in liver disease: Current evidence and potential directions. *Biochim Biophys Acta* 2017;1863(4):907-916. doi: 10.1016/j.bbadis.2017.04.023.
28. BERTOCCINI L, SENTINELLI F, LEONETTI F, BAILETTI D, CAPOCCIA D, CIMINI FA, BARCHETTA I, INCANI M, LENZI A, COSSU E, **CAVALLO MG**, BARONI MG. The vitamin D receptor functional variant rs2228570 (C>T) does not associate with type 2 diabetes mellitus. *Endocr Res.* 2017 Apr 7:1-5. doi:10.1080/07435800.2017.1305965.
29. INCANI M, SERAFINI C, SATTA C, PERRA L, SCANO F, FRONGIA P, RICCIARDI R, RIPOLI C, SORO M, STRAZZERA A, ZAMPETTI S, BUZZETTI R, **CAVALLO MG**, COSSU E, BARONI MG. High prevalence of diabetes-specific autoimmunity in first-degree relatives of Sardinian

patients with type 1 diabetes. *Diabetes Metab Res Rev*. 2016 Oct 11. doi: 10.1002/dmrr.2864. PubMed PMID: 27726307.

30. BARCHETTA I, ANGELICO F, DEL BEN M, DI MARTINO M, CIMINI FA, BERTOCCINI L, POLIMENI L, CATALANO C, FRAIOLI A, DEL VESCOVO R, MORINI S, BARONI MG, **CAVALLO MG**. Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with Type 2 diabetes. *Clin Sci (Lond)*. 2016 Oct 1;130(19):1753-62. doi: 10.1042/CS20160348. PubMed PMID: 27458255.
31. BARCHETTA I, CIMINI FA, BLOISE D, **CAVALLO MG**. Dipeptidyl peptidase-4 inhibitors and bone metabolism: is vitamin D the link? *Acta Diabetol*. 2016 Oct;53(5):839-44. doi: 10.1007/s00592-016-0882-9. PubMed PMID: 27379733.
32. BARCHETTA I, DEL BEN M, ANGELICO F, DI MARTINO M, FRAIOLI A, LA TORRE G, SAULLE R, PERRI L, MORINI S, TIBERTI C, BERTOCCINI L, CIMINI FA, PANIMOLLE F, CATALANO C, BARONI MG, **CAVALLO MG**. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *BMC Med*. 2016 Jun 29;14:92. doi: 10.1186/s12916-016-0638-y. PubMed PMID: 27353492; PubMed Central PMCID:PMC4926287.
33. SENTINELLI F, BERTOCCINI L, BARCHETTA I, CAPOCCIA D, INCANI M, PANI MG, LOCHE S, ANGELICO F, ARCA M, MORINI S, MANCONI E, LENZI A, COSSU E, LEONETTI F, BARONI MG, **CAVALLO MG**. The vitamin D receptor (VDR) gene rs11568820 variant is associated with type 2 diabetes and impaired insulin secretion in Italian adult subjects, and associates with increased cardio-metabolic risk in children. *Nutr Metab Cardiovasc Dis*. 2016 May;26(5):407-13. doi: 10.1016/j.numecd.2016.02.004. PubMed PMID: 27052925.
34. BARCHETTA I, ALESSANDRI C, BERTOCCINI L, CIMINI FA, TAVERNITI L, DI FRANCO M, FRAIOLI A, BARONI MG, **CAVALLO MG**. Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. *Eur J Endocrinol*. 2016 Feb;174(2):187-92. doi: 10.1530/EJE-15-0791. 2015 Nov 17. PubMed PMID: 26578639.
35. SENTINELLI F, CAPOCCIA D, BERTOCCINI L, BARCHETTA I, INCANI M, COCCIA F, MANCONI E, LENZI A, COSSU E, LEONETTI F, **CAVALLO MG**, BARONI MG. Search for Genetic Variant in the Apelin (APLN) Gene by Resequencing and Association Study in European Subjects. *Genet Test Mol Biomarkers*. 2016 Jan 20. PubMed PMID: 26789934.
36. BARCHETTA I, CAPOCCIA D, BARONI MG, BUZZETTI R, **CAVALLO MG**, DE COSMO S, LEONETTI F, LEOTTA S, MORANO S, MORVIDUCCI L, PRUDENTE S, PUGLIESE G, TRISCHITTA V; SUMMER Study in Diabetes Group. The "Sapienza University Mortality and Morbidity Event Rate (SUMMER) study in diabetes": Study protocol. *Nutr Metab Cardiovasc Dis*. 2015 Oct 9. pii: S0939-4753(15)30065-X. doi: 10.1016/j.numecd.2015.09.009. PubMed PMID: 26698225.
37. DI FRANCO M, BARCHETTA I, IANNUCELLI C, GERARDI MC, FRISENDA S, CECCARELLI F, VALESINI G, **CAVALLO MG**. Hypovitaminosis D in recent onset rheumatoid arthritis is predictive of reduced response to treatment and increased disease activity: a 12 month follow-up study. *BMC Musculoskelet Disord*. 2015 Mar 15;16:53. doi:10.1186/s12891-015-0505-6. PubMed PMID: 25887374; PubMed Central PMCID: PMC4373034

38. BARCHETTA I, GUGLIELMI C, BERTOCCINI L, CALELLA D, MANFRINI S, SECCHI C, POZZILLI P, **CAVALLO MG**; On behalf of the IMDIAB group. Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. *Acta Diabetol.* 2015 Feb 27. [Epub ahead of print] PubMed PMID: 25716766.
39. INCANI M, SENTINELLI F, PERRA L, PANI MG, PORCU M, LENZI A, **CAVALLO MG**, COSSU E, LEONETTI F, BARONI MG. Glycated hemoglobin for the diagnosis of diabetes and prediabetes: Diagnostic impact on obese and lean subjects, and phenotypic characterization. *J Diabetes Investig.* 2015 Jan;6(1):44-50. doi:10.1111/jdi.1224
40. BARCHETTA I, BARONI MG, LEONETTI F, DE BERNARDINIS M, BERTOCCINI L, FONTANA M, MAZZEI E, FRAIOLI A, **CAVALLO MG**. TSH levels are associated with vitamin D status and seasonality in an adult population of euthyroid adults. *Clin Exp Med.* 2014 Jun 13. PubMed PMID: 24925636.
41. BIANCHI C.; R. MICCOLI; M. TROMBETTA; F. GIORGINO; S. FRONTONI; E. FALIOIA; G. MARCHESINI; M.A. DOLCI; F. CAVALOT; MARIA GISELLA **CAVALLO**; FRIDA LEONETTI; R.C. BONADONNA; S. GENFIEV INVESTIGATORS DEL PRATO Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β -cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study 2013 *The Journal Of Clinical Endocrinology And Metabolism*, 2013, Vol. 98, p. 2100-2105, ISSN: 0021-972X, doi: 10.1210/jc.2012-3971.
42. BARCHETTA I, DE BERNARDINIS M, CAPOCCIA D, BARONI MG, FONTANA M, FRAIOLI A, MORINI S, LEONETTI F, **CAVALLO MG**. Hypovitaminosis D is Independently Associated with Metabolic Syndrome in Obese Patients. *PLoS One.* 2013 Jul 31;8(7):e68689. doi: 10.1371/journal.pone.0068689. Print 2013. PubMed PMID: 23935881; PubMed Central PMCID: PMC3729690.
43. SENTINELLI F, MINICOCCI I, MONTALI A, NANNI L, ROMEO S, INCANI M, **CAVALLO MG**, LENZI A, ARCA M, BARONI MG. Association of RXR-Gamma Gene Variants with Familial Combined Hyperlipidemia: Genotype and Haplotype Analysis. *J Lipids.* 2013;2013:517943. doi: 10.1155/2013/517943. Epub 2013
44. SENTINELLI F, INCANI M, COCCIA F, CAPOCCIA D, CAMBULI VM, ROMEO S, COSSU E, **CAVALLO MG**, LEONETTI F, BARONI MG. Association of FTO polymorphisms with early age of obesity in obese Italian subjects. *Exp Diabetes Res.* 2012;2012:872176. doi: 10.1155/2012/872176. Epub 2012 Feb 20. PubMed PMID: 22454631; PubMed Central PMCID: PMC3290805.
45. BARCHETTA I, CAROTTI S, LABBADIA G, GENTILUCCI UV, MUDA AO, ANGELICO F, SILECCHIA G, LEONETTI F, FRAIOLI A, PICARDI A, MORINI S, **CAVALLO MG**. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. *Hepatology.* 2012 Dec;56(6):2180-7. doi: 10.1002/hep.25930. PubMed PMID: 22753133.
46. **CAVALLO MG**, SENTINELLI F, BARCHETTA I, COSTANTINO C, INCANI M, PERRA L, CAPOCCIA D, ROMEO S, COSSU E, LEONETTI F, AGATI L, BARONI MG. Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus. *PLoS One.* 2012;7(12):e51236. doi: 10.1371/journal.pone.0051236. Epub 2012 Dec 5. PubMed PMID: 23227256; PubMed Central PMCID: PMC3515542.

47. BIANCHI C.; R. MICCOLI; R.C. BONADONNA; F. GIORGINO; S. FRONTONI; E. FALOIA; G. MARCHESINI; M.A. DOLCI; F. CAVALOT; MARIA GISELLA **CAVALLO**; FRIDA LEONETTI; S. DEL PRATO; O.N. BEHALF OF THE GENFIEV INVESTIGATORS Pathogenetic mechanisms and cardiovascular risk: Differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance 2012 *DIABETES CARE*, 2012, Vol. 35, p. 2607-2612, doi: 10.2337/dc11-2504.
48. BARCHETTA I, ANGELICO F, DEL BEN M, BARONI MG, POZZILLI P, MORINI S, **CAVALLO MG**. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. *BMC Med*. 2011 Jul 12;9:85. doi: 10.1186/1741-7015-9-85. PubMed PMID: 21749681;
49. DI STASIO E, MAGGI D, BERARDESCA E, MARULLI GC, BIZZARRI C, LAURIA A, PORTUESI R, **CAVALLO MG**, COSTANTINO F, BUZZETTI R, ASTORRI E, PITOCOCO D, SONGINI M, POZZILLI P; AND THE IMDIAB GROUP. Blue eyes and fair skin as risk factors for type 1 diabetes. *Diabetes Metab Res Rev*. 2011 May 6. doi: 10.1002/dmrr.1214 PubMed PMID: 2155
50. BARCHETTA I, RICCIERI V, VASILE M, STEFANANTONI K, COMBERIATI P, TAVERNITI L, **CAVALLO MG**. High prevalence of capillary abnormalities in patients with diabetes and association with retinopathy. *Diabet Med*. 2011 Apr 25. doi: 10.1111/j.1464-5491.2011.03325.x.
51. BIANCHI C, MICCOLI R, BONADONNA RC, GIORGINO F, FRONTONI S, FALOIA E, MARCHESINI G, DOLCI MA, ALVIGGI L, GNASSO A, CONSOLI A, CAVALOT F, **CAVALLO MG**, LEONETTI F, GIACCARI A, DEL PRATO S; On Behalf of the GENFIEV Investigators. Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. *Nutr Metab Cardiovasc Dis*. 2011 Sep;21(9):699-705. doi: 10.1016/j.numecd.2010.03.006
52. BIZZARRI C, PITOCOCO D, NAPOLI N, DI STASIO E, MAGGI D, MANFRINI S, SURACI C, **CAVALLO MG**, CAPPÀ M, GHIRLANDA G, POZZILLI P; IMDIAB GROUP. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. *Diabetes Care*. 2010 Sep;33(9):1962-3.
53. CAMBULI VM, INCANI M, COSSU E, CONGIU T, SCANO F, PILIA S, SENTINELLI F, TIBERTI C, **CAVALLO MG**, LOCHE S, BARONI MG. Prevalence of type 1 diabetes autoantibodies (GADA, IA2, AND IAA) in overweight and obese children. *Diabetes care*. 2010 apr;33(4):820-2.
54. BARCHETTA I, SPERDUTI L, GERMANÒ G, VALIANTE S, VESTRI A, FRAIOLI A, BARONI MG, **CAVALLO MG**. Subclinical Vascular Alterations In Young Adults With Type 1 Diabetes Detected By Arterial Tonometry. *Diabetes Metab Res Rev*. 2009 NOV;25(8):756-61.
55. CAMBULI VM, INCANI M, PILIA S, CONGIU T, **CAVALLO MG**, COSSU E, SENTINELLI F, MARIOTTI S, LOCHE S, BARONI MG. Oral Glucose Tolerance Test In Italian Overweight/Obese Children And Adolescents Results In A Very High Prevalence Of Impaired Fasting Glycaemia, But Not Of Diabetes. *Diabetes Metab Res Rev*. 2009 Sep;25(6):528-34.
56. CAMBULI VM, MC MUSIU, M INCANI, M PADERI, R SERPE, V MARRAS, E COSSU, **MG CAVALLO**, S MARIOTTI, S LOCHE AND MG BARONI. Assessment of adiponectin and

leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children. *J Clin Endocrinology Metabolism* 2008 Aug;93:3051-7

57. **CAVALLO MG**, POZZILLI P, MISITI S AND BARONI MG. Editorial. Insulinoma CM cell line as in vitro model for beta-cell. *Journal Cell Physiology*. 216 (2): 568, 2008.
58. ROMEO S, SENTINELLI F, **CAVALLO MG**, LEONETTI F, FALLARINO M, MARIOTTI S AND BARONI MG. Search for genetic variants of the SYNTAXIN 1A (STX1A) gene: the -352 A>T variant in the STX1A promoter associates with impaired glucose metabolism in an Italian obese population. *International Journal of Obesity*, Mar 3 2(3): 413- 420, 200
59. PITOCCO D, DISTASIO E, CRINÒ A, MANFRINI S, GUGLIELMI C, VISALLI N, SURACI C, MATTEOLI MC, **CAVALLO MG**, BIZZARRI C, POZZILLI P; IMDIAB GROUP. Age at diagnosis of type 1 diabetes and the effect of immunomodulatory therapies on residual beta cell function. *Horm Metab Res*. 2008 Jan;40(1):66-8.
60. PITOCCO D, CRINÒ A, DI STASIO E, MANFRINI S, GUGLIELMI C, SPERA S, ANGUISSOLA GB, VISALLI N, SURACI C, MATTEOLI MC, PATERA IP, **CAVALLO MG**, BIZZARRI C, POZZILLI P; IMDIAB GROUP. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). *Diabet Med*. 2006 Aug;23(8):920-3.
61. SENTINELLI F, FILIPPI E, **CAVALLO MG**, ROMEO S, FANELLI M, BARONI MG. The G972R variant of the insulin receptor substrate-1 gene impairs insulin signaling and cell differentiation in 3T3L1 adipocytes; treatment with a PPARgamma agonist restores normal cell signaling and differentiation. *J Endocrinol*. 2006 Feb;188(2):271-85
62. GENOVESE S, BAZZIGALUPPI E, GONCALVES D, CIUCCI A, **CAVALLO MG**, PURRELLO F, ANELLO M, ROTELLA CM, BARDINI G, VACCARO O, RICCARDI G, TRAVAGLINI P, MORENGHI E, BOSI E, POZZILLI P. Clinical phenotype and beta-cell autoimmunity in Italian patients with adult-onset diabetes. *Eur J Endocrinol*. 2006 Mar;154(3):441- 7.
63. VERGA FALZACAPPA C, PANACCHIA L, BUCCI B, STIGLIANO A, **CAVALLO MG**, BRUNETTI E, TOSCANO V, MISITI S. 3,5,3'-triiodothyronine (T3) is a survival factor for pancreatic beta-cells undergoing apoptosis. *J Cell Physiol*. 2006 206(2)309-21
64. **CAVALLO MG**, MONTALI A, MONETINI L, VALENTE L, MARIANI P, BIFOLCO M, SIRINIAN MI, ANTONINI TM, FIORETTI F, CAMPAGNA F, VERNA R, ARCA M. Tumor necrosis factor alpha and its soluble receptor p75 (sTNF-R p75) in familial combined hyperlipidemia (FCHL). *Nutr Metab Cardiovasc Dis*. 2005 Aug;15(4):262-9.
65. POZZILLI P, MANFRINI S, COSTANZA F, COPPOLINO G, **CAVALLO MG**, FIORITI E, MODI P. Biokinetics of buccal spray insulin in patients with type 1 diabetes. *Metabolism*. 2005 Jul;54(7):930-4.
66. ANGELICO F, DEL BEN M, CONTI R, FRANCIOSO S, FEOLE K, FIORELLO S, **CAVALLO MG**, ZALUNARDO B, LIRUSSI F, ALESSANDRI C, VIOLI F. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. *J Clin Endocrinol Metab*. 2005 Mar; 90(3):1578-82.
67. MONETINI L, **CAVALLO MG**, SARUGERI E, SENTINELLI F, STEFANINI L, BOSI E, THORPE R, POZZILLI P; IMMUNOTHERAPY DIABETES (IMDIAB) GROUP. Cytokine profile and insulin antibody IgG subclasses in patients with recent onset type 1 diabetes treated with oral insulin. *Diabetologia*. 2004 Oct;47(10):1795-802.
68. MONETINI L, BARONE F, STEFANINI L, PETRONE A, WALK T, JUNG G, THORPE R, POZZILLI P, **CAVALLO MG**. Establishment of T cell lines to bovine beta-casein and beta-

- casein-derived epitopes in patients with type 1 diabetes. *J Endocrinol.* 2003;176(1):143-50.
69. MONETINI L, **CAVALLO MG**, MANFRINI S, STEFANINI L, PICARELLI A, DI TOLA M, PETRONE A, BIANCHI M, LA PRESA M, DI GIULIO C, BARONI MG, THORPE R, WALKER BK, IMDIAB GROUP, POZZILLI P. Antibodies to bovine Beta-casein in diabetes and other autoimmune diseases. *Horm Metab Res.* 2002 Aug;34(8):455-9.
 70. **CAVALLO MG**, ROMEO S, COPPOLINO G, POZZILLI P. Inhaled insulin in type 1 diabetes. *Lancet.* 2001 Jun 16;357(9272):1979-80.
 71. MONETINI L, **CAVALLO MG**, STEFANINI L, FERRAZZOLI F, BIZZARRI C, MARIETTI G, CURRO V, CERVONI M, POZZILLI P
Bovine beta-casein antibodies in breast- and bottle-fed infants: their relevance in Type 1 diabetes. *Diabetes Metab Res Rev.* 2001 Jan-Feb;17(1):51-4
 72. **CAVALLO MG**, ROMEO S, COPPOLINO G, POZZILLI P. Continuous glucose monitoring during the European Soccer cup semifinal, Italy against Holland. *Diabetologia.* 2001 Feb;44(2):268.
 73. CRINO A, **CAVALLO MG**, CORBI S, MESTURINO CA, FERRAZZOLI F, COPPOLINO G, BIZZARRI C, CERVONI M, MONETINI L, POZZILLI P. Intradermal skin test with diabetes specific antigens in patients with type 1 diabetes. *Clin Exp Immunol.* 2001 Mar;123(3):382-6.
 74. BURKART V, LIU H, BELLMANN K, WISSING D, JAATTELA M, **CAVALLO MG**, POZZILLI P, BRIVIBA K, KOLB H. Natural resistance of human beta cells toward nitric oxide is mediated by heat shock protein 70. *J Biol Chem.* 2000 Jun 30;275(26):19521-8
 75. POZZILLI P, **CAVALLO MG**. Oral insulin and the induction of tolerance in man *Diabetes Metabolism Research Reviews* 16: 306-307, 2000
 76. POZZILLI P, PITOCCO D, VISALLI N, **CAVALLO MG**, BUZZETTI R, CRINO' A, SPERA S, MULTARI G, CERVONI M, MANCA BITTI ML, MATTEOLI MC, MARIETTI G, CASSONE FALDETTA MR, GIORDANO C, SBRIGLIA M, SAUGERI E, GHIRLANDA G AND THE IMDIAB GROUP. No effect of oral insulin on residual beta-cell function in recent-onset Type 1 diabetes (the IMDIAB VII). *Diabetologia* 43:1000-1004, 2000
 77. VISALLI N, **CAVALLO MG**, SIGNORE A, BARONI MG, BUZZETTI R, FIORITI E, MESTURINO C, FIORI R, LUCENTINI L, MATTEOLI MC, CRINÒ A, CORBI S, SPERA S, TEODONIO C, PACI F, AMORETTI R, PISANO L, SURACI C, MULTARI G, SULLI N, CERVONI M, DE MATTIA G, CASSONE FALDETTA MR, BOSCHERINI B, MANCA BITTI ML, MARIETTI G, FERRAZZOLI F, BIZZARRI C, PITOCCO D, GHIRLANDA G, POZZILLI P. A multi-centre randomised trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (The IMDIAB VI). *Diabetes/Metabolism Research and Reviews* 15:181-5, 1999.
 78. BARONI MG, **CAVALLO MG**, MARK M, MONETINI L, STOEHER B, POZZILLI P. b-cell genes mRNA expression and functional characterization of the human insulinoma cell line CM. *Journal of Endocrinology* 161, 59-68 1999.
 79. MONETINI L, **CAVALLO MG**, BARONE F, VALENTE L, RUSSO M, WALKER B, THORPE R, POZZILLI P. T cell reactivity to human insulinoma cell line (CM) antigens in patients with type 1 diabetes. *Autoimmunity* 29: 171-177, 1999.
 80. BARONI MG, D'ANDREA MP, CAPICI F, BUZZETTI R, **CAVALLO MG**, FALLUCCA F, GIOVANNINI C, POZZILLI P High frequency of polymorphism but no mutations found in

the GLUT1 glucose transporter gene in NIDDM and familial obesity by SSCP analysis. *Hum Genet* 1998 Apr;102(4):479-82

81. SCHWINGSHACKL A, BLASKO I, STEINER E, POZZILLI P, **CAVALLO MG**, BERGER P, GRUBECK-LOEBENSTEIN B Sex steroids do not prevent amylin-induced apoptosis in human cells. *Exp Cell Res* 1998 May 25;241(1):265-8
82. POZZILLI P, VISALLI N, BUZZETTI R, **CAVALLO MG**, MARIETTI G, HAWA M, LESLIE RD Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population-based study. IMDIABStudy Group. *Metabolism* 1998 Oct;47(10):1205-10
83. **CAVALLO MG**, MONETINI L, VALENTE L, BARONE F, BEALES PE, RUSSO M, POZZILLI P. Glutathione protects a human insulinoma cell line from tumor necrosis factor- - mediated cytotoxicity. *International Journal of Clinical & Laboratory Research*, 27:44-47, 1997.
84. VISALLI N, SIGNORE A, BARONI MG, BUZZETTI R, **CAVALLO MG**, BOCCUNI ML, VALENTE L, MESTURINO C, ANDREANI D ET AL. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin dependent diabetes (The IMDIAB IV Study). *European Journal of Endocrinology*, 1997 Sep;137(3):234-9.
85. WILD T, SCHERBAUM WA, GLEICHMANN H, LANDT M, SANTIAGO J, ENDL, LANDGRAF R, **CAVALLO MG**, GANZ M, POZZILLI P. Comparison of a new anti-glutamic acid decarboxylase (GAD) enzyme-linked immune absorbant assay (ELISA) with two radioimmunoassay methods: a multicenter study. *Hormone and Metabolic Research*, 1997 Aug;29(8):403-6
86. **CAVALLO MG**, POZZILLI P. Pilot trials in pre-IDDM *Diabetes Metab Rev.* 1997 Dec;13(4):316.
87. **CAVALLO MG**, MONETINI L, RUSSO M, THORPE R, POZZILLI P. Mumps virus infection increases sensitivity to tumor necrosis factor-alpha and gamma-interferon induced cytotoxicity in a human insulinoma cell line. *Diabetes Nutrition and Metabolism*, 8:319-323, 1995.
88. **CAVALLO MG**, F DOTTA, L MONETINI, S. DIONISI, M PREVITI, A TOTO, U. DI MARIO, P POZZILLI. Beta cell markers and autoantigen expression by a human insulinoma cell line: similarities to native beta cells. *Journal of Endocrinology* 150: 113-120, 1996
89. **CAVALLO MG**, FAVA D, MONETINI L, BARONE F, POZZILLI P. Cell mediated Immune response to beta casein in recent onset insulin dependent diabetes: implications for disease pathogenesis. *Lancet* 348: 926-928, 1996.
90. **CAVALLO MG**, MONETINI L, WALKER B, THORPE R, POZZILLI P. Diabetes and cows' milk. *Lancet* 348:1655,1996. (research letter)
91. POZZILLI P, VISALLI N, BUZZETTI R, BARONI MG, BOCCUNI ML, FIORITI E, SIGNORE A, **CAVALLO MG**, ANDREANI D, et al. Immunotherapy in recent onset insulin-dependent diabetes mellitus and insulin requirement after 2 years. *Diabete & Metabolisme* 21:47-49, 1995.
92. POZZILLI P, VISALLI N, SIGNORE A, BARONI MG, BUZZETTI R, **CAVALLO MG**, BOCCUNI ML, ANDREANI D, et al. Double blind trial of Nicotinamide in recent onset insulin-dependent diabetes mellitus. *Diabetologia* 38:848-852, 1995.
93. **CAVALLO MG**, P. POZZILLI THORPE R. Cytokines and autoimmunity. *Clinical Experimental Immunology*, 96:1-7, 1994

94. BARONI MG, ALCOLADO JC, GRAGNOLI C, FRANCIOSI AM, **CAVALLO MG**, FIORE V, POZZILLI P, GALTON DJ. Affected sib-pair analysis of the GLUT-1 glucose transporter gene locus in non-insulin-dependent diabetes mellitus (NIDDM) evidence for linkage. *Human genetics* 93: 675- 680, 1994.
95. POZZILLI P, VISALLI N, BOCCUNI ML, BARONI MG, BUZZETTI R, FIORITI E, SIGNORE A, **CAVALLO MG** et al. Combination of nicotinamide and steroid versus nicotinamide in recent onset insulin-dependent diabetes (The IMDIAB II Study). *Diabetes Care*, 17:897-900, 1994
96. POZZILLI P, VISALLI N, BOCCUNI ML, BARONI MG, BUZZETTI R, FIORITI E, SIGNORE A, **CAVALLO MG**, ANDREANI D, et al. Randomized Trial Comparing Nicotinamide and Nicotinamide plus Cyclosporin in Recent onset Insulin-dependent Diabetes. *Diabetic Medicine*, 11:98-104, 1994
97. **CAVALLO MG**, BARONI MG, TOTO A, GEARING A, ANDREANI D, THORPE P, POZZILLI P. Viral infection induces cytokine release by beta cells. *Immunology* 75:664-668, 1992.
98. BARONI MG, ALCOLADO J, POZZILLI P, **CAVALLO MG**, LI SR, GALTON D. Polymorphisms at the GLUT2 (beta-cell/cell) glucose transporter gene and non-insulin-dependent diabetes mellitus (NIDDM) analysis in affected pedigree members. *Clinical Genetics* 41:229-234, 1992
99. **CAVALLO MG**, POZZILLI P, BIRD C, WADHWA M, MEAGER A, VISALLI N, GEARING AJH, ANDREANI D, THORPE R. Cytokines in sera from insulin-dependent diabetic patients at diagnosis. *Clinical and Experimental Immunology*, 86:256-259, 1991.
100. **CAVALLO MG**, SIGNORE A, BARONI MG, ANDREANI D, POZZILLI P: Interleukin 2 (IL2) production and IL2 receptor release in Type 1 diabetes mellitus. *Diabetes Nutrition and Metabolism* 2: 179-183, 1989.
101. POZZILLI P, VISALLI N, **CAVALLO MG**, BEALES P, NEGRI M, GHIRLANDA G, PAPA V, ANDREANI D: Normalization of the CD4/CD8 lymphocyte ratio and increased B lymphocytes in long standing diabetic patients following therapy with thymopentin. *Diabetes Research* 6: 51-56, 1987.
102. POZZILLI P, GALE EAM, VISALLI N, BARONI MG, CROVARI P, FRIGHI V, **CAVALLO MG**, ANDREANI D: The immune response to influenza vaccination in diabetic patients. *Diabetologia* 29: 850-854, 1986.